An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Cancer|Non-small Cell Lung Cancer (NSCLC)
DRUG: Cofetuzumab Pelidotin
Objective Response Rate (ORR), ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR)., Up to approximately 3 years
Duration of Response (DOR), DOR is defined as the time from the participant's initial response (CR or PR) to the first occurrence of radiographic progression or death from any cause., Up to approximately 3 years|Progression Free Survival (PFS), PFS is defined as the time from the participant's first dose of study drug until radiographic progression or death from any cause., Up to approximately 3 years|Overall Survival (OS), OS is defined as the time from the participant's first dose of study drug until death from any cause., Up to approximately 3 years
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.